The Lymphoma Academic Research Organisation
Quick facts
| Founded | 2000 |
|---|
Marketed products
- Vinblastin · Oncology
Phase 3 pipeline
- Mosunetuzumab (SC) · Oncology
Mosunetuzumab is a bispecific antibody that simultaneously engages CD20 on B cells and CD3 on T cells to redirect T cell killing of B cell lymphomas. - R-CHOP / R-HAD · Oncology
R-CHOP/R-HAD is a combination chemotherapy regimen that uses rituximab (an anti-CD20 monoclonal antibody) plus alternating cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and HAD (high-dose cytarabine, doxorubicin, dexamethasone) to target B-cell lymphomas. - RCHOP21 · Oncology
Rituximab targets and depletes CD20-positive B cells, while cyclophosphamide, doxorubicin, and prednisone work through various mechanisms to induce cell death in cancer cells. - Rituximab - CHOP · Oncology
Rituximab is a monoclonal antibody that binds to CD20 on B cells and triggers their destruction, used in combination with CHOP chemotherapy to treat lymphomas. - Rituximab - CVP · Oncology
Rituximab is a monoclonal antibody that binds to CD20 on B cells and triggers their destruction, combined with CVP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) to treat lymphoma. - Romidepsin + CHOP · Oncology
Romidepsin inhibits histone deacetylases to promote cancer cell death, combined with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) for multi-modal lymphoma treatment.
Phase 2 pipeline
- Aracytine · Other
- Brentuximab Vedotin - induction · Oncology
Brentuximab vedotin is a monoclonal antibody-drug conjugate that targets CD30, a protein often found on the surface of Hodgkin lymphoma and anaplastic large cell lymphoma cells. - Brentuximab Vedotin - maintenance
- Lenalidomide and R-CHOP
- RO7082859
- Venetoclax Oral Product
Phase 1 pipeline
- Everolimus and rituximab
- Lenalidomide and GA101
- Rituximab, CMC544, Gemcitabine and Oxaliplatine
- Romidepsin and CHOP
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- The Lymphoma Academic Research Organisation portfolio CI brief
- The Lymphoma Academic Research Organisation pipeline updates RSS
Frequently asked questions about The Lymphoma Academic Research Organisation
What are The Lymphoma Academic Research Organisation's marketed drugs?
Top marketed products include Vinblastin.
What is The Lymphoma Academic Research Organisation's pipeline?
The Lymphoma Academic Research Organisation has 6 drugs in Phase 3, 6 in Phase 2, 4 in Phase 1. Late-stage candidates include Mosunetuzumab (SC), R-CHOP / R-HAD, RCHOP21, Rituximab - CHOP.
When was The Lymphoma Academic Research Organisation founded?
The Lymphoma Academic Research Organisation was founded in 2000.
Related
- Vinblastin · Oncology
- Sector hub: All tracked pharma companies